Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2013

Study Completion Date

January 31, 2015

Conditions
Breast Cancer
Interventions
DRUG

Everolimus

Everolimus tablets, two-5 mg tablets a day

DRUG

Fulvestrant

intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter

Trial Locations (1)

40536

University of Kentucky, Lexington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Mara Chambers

OTHER